Project Name：Cabazitaxel 

Registration Classification：3.1

Formulations and specifications ：Injection 60mg/1.5ml (40mg/ml) 

Indications：This product is applied to previous treatment of  hormone refractory metastatic prostate cancer with prednisone combined with docetaxel -containing treatment regimen in patients with

Original Research Company：Sanofi-Aventis 

Progress ：Pharmaceutical Research in progress